CoChat
Sign Up
Cited by 250Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsLiver Diseases and Immunity

From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease

Open access
Rinella, Mary E., Sookoian, Silvia·2024·Journal of Lipid Research
DOI 10.1016/j.jlr.2023.100485PMC PMC10824973
Open this paper in CoChat — free accountOpen PDF

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a prevalent chronic liver disease worldwide, affecting more than 30% of the global population (1;2). Importantly, MASLD is a multifaceted disorder resulting from complex interactions with various cardiometabolic and environmental risk factors (3-5).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jlr.2023.100485

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The clinical definition of MASLD includes not only steatosis but also a cardiometabolic context, which cannot be fully reproduced in a monoculture of hepatocyte-like cells.

    “This is because the clinical definition of MASLD, as previously noted, includes not only the presence of steatosis but also a cardiometabolic context [31,32,33], which cannot be fully reproduced in a monoculture of hepatocyte-like cells.”

    From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [33]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 24 · Cited by 250

Research works printed but not linked: 18

  1. [2]Yip T.C. Vilar-Gomez E. Petta S. Yilmaz Y. Wong G.L. Adams L.A. Geographical similarity and differences in the burden and genetic predisposition of NAFLD Hepatology 77 2023 1404 1427 36062393
  2. [4]Powell E.E. Wong V.W. Rinella M. Non-alcoholic fatty liver disease Lancet 397 2021 2212 2224 33894145
  3. [5]Sookoian S. Pirola C.J. How safe is moderate alcohol consumption in overweight and obese individuals? Gastroenterology 150 2016 1698 1703 26775630
  4. [6]Eslam M. Sanyal A.J. George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease Gastroenterology 158 2020 1999 2014 32044314
  5. [7]Ludwig J. Viggiano T.R. McGill D.B. Oh B.J. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease Mayo Clin. Proc. 55 1980 434 438 7382552
  6. [8]Arrese M. Arab J.P. Barrera F. Kaufmann B. Valenti L. Feldstein A.E. Insights into nonalcoholic fatty-liver disease heterogeneity Semin. Liver Dis. 41 2021 421 434 34233370 PMC8492194
  7. [9]Pirola C.J. Sookoian S. Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making Expert Rev. Gastroenterol. Hepatol. 17 2023 317 324 36912694
  8. [10]Sookoian S. Pirola C.J. Valenti L. Davidson N.O. Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology Hepatology 72 2020 330 346 32170962 PMC7363530
  9. [11]Friedman S.L. Neuschwander-Tetri B.A. Rinella M. Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies Nat. Med. 24 2018 908 922 29967350 PMC6553468
  10. [12]Pirola C.J. Sookoian S. The lipidome in nonalcoholic fatty liver disease: actionable targets J. Lipid Res. 62 2021 100073 PMC8121699 33845089
  11. [13]Wong V.W. Adams L.A. de Lédinghen V. Wong G.L. Sookoian S. Noninvasive biomarkers in NAFLD and N Nat. Rev. Gastroenterol. Hepatol. 15 2018 461 478 29844588
  12. [16]Rinella M.E. Lazarus J.V. Ratziu V. Francque S.M. Sanyal A.J. Kanwal F. A multisociety Delphi consensus statement on new fatty liver disease nomenclature Hepatology 78 2023 1966 1986 37363821 PMC10653297
  13. [17]Younossi Z.M. AlQahtani S.A. Alswat K. Yilmaz Y. Keklikkiran C. Funuyet-Salas J. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease J. Hepatol. S0168-8278 2023 05279 05280 37984709
  14. [19]Sanyal A.J. Shankar S.S. Calle R.A. Samir A.E. Sirlin C.B. Sherlock S.P. Non-invasive biomarkers of nonalcoholic steatohepatitis: the FNIH NIMBLE project Nat. Med. 28 2022 430 432 35145308 PMC9588405
  15. [20]Aberg F. Byrne C.D. Pirola C.J. Mannisto V. Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease J. Hepatol. 78 2023 191 206 36063967
  16. [21]Lazarus J.V. Romero D. Kopka C.J. Karim S.A. Abu-Raddad L.J. Almeida G. A multinational Delphi consensus to end the COVID-19 public health threat Nature 611 2022 332 345 36329272 PMC9646517
  17. [22]Ratziu V. Boursier J. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD J. Hepatol. S0168-8278 2023 04996 05006 37543307
  18. [24]Lee C. Yoon E. Kim M. Kang B. Cho S. Nah E. Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings Hepatology 2023 10.1097/HEP.0000000000000664 38100294 · DOI

Authors
Rinella, M. E., & Sookoian, S.
Affiliations
  • University of Chicago (US)
  • Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
Corresponding author
  • Rinella, Mary E.
  • Sookoian, Silvia
ORCID
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2024-01
Volume
65
Issue
1
Pages
100485
ISSN
0022-2275 (ISSN-L)
DOI
10.1016/j.jlr.2023.100485
PMC
PMC10824973
OpenAlex
W4389719915
Cited by
250
References
24
Citations by year
2026: 93 · 2025: 109 · 2024: 48
FWCI
49.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Lipid Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
non-alcoholic fatty liver disease, disease nomenclature, diagnostic criteria, chronic liver disease, cardiometabolic risk factors
MeSH terms
Humans, Terminology as Topic, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review